At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
Daily administration: 2 tablets FaseMETS a daydietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot, Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS in Metabolic Syndrome
In Brief
A clinical study evaluating Daily administration: 2 tablets FaseMETS a day for Metabolic Syndrome. Completed, enrolled 34 participants across 2 sites.
Detailed Summary
The primary objective is to evaluate the efficacy of FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome; The secondary objectives of the trial are: * to evaluate the potential benefit after 3 months of therapy (by an interim analysis) * to evaluate the safety of FaseMETS
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesRomania
CollaboratorsOpera CRO, a TIGERMED Group Company
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartMay 2017
Primary CompletionOct 2017
Study CompletionJun 2018
TodayJul 2026
First PostedSep 23, 2016
Enrollment StartMay 9, 2017
Primary CompletionOct 15, 2017
Study CompletionJun 11, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.8 years ago
Interventions
Daily administration: 2 tablets FaseMETS a daydietary
Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome